Andreas Tridimas: Atherosclerosis Is Greyer Than We Admit
Andreas Tridimas, Consultant in Chemical Pathology and Metabolic Medicine at Wirral University Teaching Hospital NHS Foundation Trust, shared a post on LinkedIn:
“Maybe the honest thing to say is that atherosclerosis is greyer than we like to admit. We all have patients with dreadful disease and nothing obvious against them, and patients with terrible lipids and clean arteries into their eighties. Whatever the alchemy is, we clearly haven’t got it yet.
ZEUS was the same story a few weeks ago. Ziltivekimab lowered IL 6 and hsCRP exactly as designed, and the hazard ratio came out at 0.99. Hit the target, miss the disease. Twice now this year.
Part of it may be that Mendelian randomisation and a trial like this aren’t studying the same people. MR captures a variant acting from conception on a healthy artery across six decades, while HORIZON took patients at 59 who’d already had their event and treated them for five years. That tells you the biology matters. It doesn’t tell you the analyte is still modifiable once the damage is done.
What it doesn’t change is what I do on Monday morning. Get the LDL down and keep it down, treat the blood pressure, sort the diabetes, talk properly about diet, weight, exercise and smoking. If anything I’ll push harder on all of that in someone with a high Lp(a), because right now that’s the risk I can actually do something about.
So I’m not going to pretend I know what Horizon means yet. We’ve had a conclusion without any numbers. Let’s wait an see the full data set at AHA in November.”

Stay updated with Hemostasis Today.
-
Oct 23, 2026, 16:05Platelet Secretion Defects and Their Role in the Diagnosis of Bleeding Disorders
-
Oct 23, 2026, 16:00Hemophilia Alliance team in New Orleans at the ATHN Data Summit
-
Oct 23, 2026, 15:49Brian Sapp: Why Exact Calf Vein Naming Is Critical for DVT Diagnosis?
-
Oct 23, 2026, 15:33Smitirupa Mishra: A Systematic Approach to Bone Marrow Examination
-
Oct 23, 2026, 15:29José Antonio García Erce: Preoperative Anemia Emerges as a Modifiable Surgical Risk in New POWER Study
-
Oct 23, 2026, 15:13Reza Shojaei: Manufactured Red Blood Cells vs Blood Donation
-
Oct 23, 2026, 14:29Jean Jacques Kiladjian: International Scientific Exchange at IHCAMS in Tianjin
-
Oct 23, 2026, 14:11Aravind Palraj: The Prolonged aPTT Puzzle in SLE
-
Oct 23, 2026, 13:56Chokri Ben Lamine: The Evolving Treatment Landscape of Persistent and Chronic ITP